- Brand names:
- Pharmaceutical Company:
- Condition/Indication: High grade epithelial ovarian; fallopian tube; or primary peritoneal cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 364KB)
Niraparib – March 2022
Niraparib: Capsule 100 mg; Zejula®
Last updated
1 July 2022